Epstein-Barr virus polymerase chain reaction-negative stage IV post-transplant lymphoproliferative disorder in a heart transplant patient treated with rituximab

Patrick Garceau; Christian Couture; Bernard Cantin; Vincent Bernier; Mario Sénéchal

doi:10.1016/j.healun.2008.05.020

Epstein-Barr virus polymerase chain reaction-negative stage IV post-transplant lymphoproliferative disorder in a heart transplant patient treated with rituximab

J Heart Lung Transplant. 2008 Aug;27(8):928-31. doi: 10.1016/j.healun.2008.05.020. Epub 2008 Jul 3.

Authors

Patrick Garceau¹, Christian Couture, Bernard Cantin, Vincent Bernier, Mario Sénéchal

Affiliation

¹ Institut de Cardiologie de Québec, Hôpital Laval, Sainte-Foy, Québec, Canada.

PMID: 18656811
DOI: 10.1016/j.healun.2008.05.020

Abstract

Post-transplant lymphoproliferative disorder (PTLD) is often associated with Epstein-Barr virus (EBV). However, in this report, we describe a heart transplant recipient with pathologically proven EBV-positive PTLD with undetectable virus by polymerase chain reaction. The patient had remission after anti-CD20 antibody treatment early after transplantation.

Publication types

Case Reports

MeSH terms

Adolescent
Antibodies / therapeutic use
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Murine-Derived
Antigens, CD20
Epstein-Barr Virus Infections / diagnosis*
Epstein-Barr Virus Infections / drug therapy*
Heart Transplantation*
Herpesvirus 4, Human
Humans
Immunologic Factors / therapeutic use*
Lymphoproliferative Disorders / diagnosis*
Lymphoproliferative Disorders / drug therapy*
Lymphoproliferative Disorders / virology
Male
Polymerase Chain Reaction
Rituximab
Treatment Outcome
Viral Load

Substances

Antibodies
Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Antigens, CD20
Immunologic Factors
Rituximab